What are your top takeaways in GU Cancers from ESMO 2025?

1. KEYNOTE-905: These impressive results change the management paradigm of patients with MIBC who are surgical candidates but are not cisplatin-eligible. Over time, it may be that EVP perioperative therapy becomes the standard of care for all patients with MIBC with plans to proceed with cystectomy.
2. I...

1. EV-303/KEYNOTE-905: Peri-operative EV/pembrolizumab in cisplatin-ineligible patients with MIBC.
2. IMvigor011: Adjuvant atezolizumab vs placebo based on ctDNA.
3. RC48-C016 (China): Disitamab vedotin + toripalimab vs gemcitabine + (cisplatin or carboplatin) in the frontline metastatic urothelial Ca setti...

1. EV-303: Practice-changing trial with EV/Pembro now potentially becoming the new SOC for cisplatin-ineligible patients with MIBC.
2. Imvigor011: First trial showing ctDNA to be a predictive biomarker for ICI treatment in patients with high-risk MIBC following cystectomy. Also first trial to show OS adv...

I think all 3 of the Presidential Symposium presentations were impactful - EV-303, IMvigor011, and the DV + toripalimab:

1. EV-303 is practice-changing once approved.
2. IMvigor011 shows the value of assigning therapy based on ctDNA, and
3. DV study, while done in China, had an impressive ORR and PFS/OS, whi...

1. PSMAddition

This Presidential Symposium presentation by Tagawa and colleagues reported on a randomized trial of up to 6 cycles of Lu-177-PSMA-617 plus ADT/ARPI vs ADT/ARPI alone in 1144 men with PSMA PET+ mHSPC. These patients were selected based on prior VISION criteria and deemed not permitted t...

1. PSMAaddition in mHSPC
2. CAPItello-281 in mHSPC
3. Neoadjuvant EVP in MIBC